U.S. Insulin Price Rises May Open Way For Biosimilars, Says Novo CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
The dominant position in the U.S. insulin market enjoyed by Sanofi and Novo Nordisk allowed them to raise prices again recently, but that ability represents a double-edged sword, according to the Danish insulin maker’s CEO, because excessive increases may open the way there for alternative biosimilar products.
You may also be interested in...
Novo Nordisk Withholding Tresiba From German HTA Process
Withholding Tresiba from Europe’s biggest drug market seems counterintuitive in view of the ultra-long-acting insulin’s spreading acceptance elsewhere. But in doing so, Novo avoids having Germany’s reimbursement authorities questioning its benefits and demanding a price cut.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.